{"id":"W4311575712","doi":"10.1186/s12876-022-02590-6","title":"Evaluating cost per remission and cost of serious adverse events of advanced therapies for ulcerative colitis","year":2022,"lang":"en","type":"article","venue":"BMC Gastroenterology","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Western University","funders":"Takeda Pharmaceuticals U.S.A.","keywords":"Tofacitinib; Medicine; Vedolizumab; Adalimumab; Infliximab; Golimumab; Adverse effect; Ulcerative colitis; Number needed to treat; Ustekinumab; Internal medicine; Cost effectiveness; Relative risk; Confidence interval; Rheumatoid arthritis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005516623,0.001035629,0.001183806,0.002451674,0.0002522185,0.001536243,0.001237507,0.0008347254,0.003022808],"category_scores_gemma":[0.01884175,0.0005773088,0.004473331,0.002781117,0.0004616384,0.001440529,0.0008141454,0.001160697,0.000193651],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.006466893,"about_ca_system_score_gemma":0.003840681,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01938327,"about_ca_topic_score_gemma":0.01420679,"domain_scores_codex":[0.9969579,0.002206253,0.000166416,0.0001872282,0.0003058868,0.0001763918],"domain_scores_gemma":[0.9860159,0.01129903,0.001576347,0.0002619084,0.0005848882,0.0002619404],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","study_design_scores_codex":[0.002269149,0.0003207407,0.05485962,0.00146886,0.006976582,0.0001966659,0.00007292331,0.8858182,0.0002753107,0.009171951,0.002307343,0.03626267],"study_design_scores_gemma":[0.0009447323,0.001625025,0.03861872,0.0009634068,0.007962458,0.0004844841,0.0002233807,0.9270037,0.000722796,0.01457168,0.006762859,0.0001166404],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8892637,0.0284346,0.04827252,0.004292898,0.0002030829,0.00136066,0.0130039,0.0001541988,0.0150144],"genre_scores_gemma":[0.9837909,0.003496505,0.008810876,0.0001881553,0.00004236298,0.0004606851,0.002322056,0.00002547716,0.0008629691],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01938327,"threshold_uncertainty_score":0.04692084,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01790258519806624,"score_gpt":0.3036175472860557,"score_spread":0.2857149620879894,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}